Advisory Committee Meeting Will Focus On Fablyn’s Mortality Trend
This article was originally published in The Pink Sheet Daily
Executive Summary
If approved, the osteoporosis drug may struggle to compete with Lilly’s Evista, according to PEARL data.
You may also be interested in...
FDA Advisory Panel Undecided On Fablyn’s Mortality Trend
Reproductive Health Drugs advisory panel concludes the benefits of Pfizer’s lasofoxifene outweigh its risks in specific populations of women with postmenopausal osteoporosis.
FDA Advisory Panel Undecided On Fablyn’s Mortality Trend
Reproductive Health Drugs advisory panel concludes the benefits of Pfizer’s lasofoxifene outweigh its risks in specific populations of women with postmenopausal osteoporosis.
Pfizer’s Oporia Is “Not Approvable” For Osteoporosis Prevention
The company says it will consider “various possible courses of action” following FDA’s decision on the selective estrogen receptor modulator.